The MarketWatch News Department was not involved in the creation of this content. Cure HHT plays pivotal role in the NIH-sponsored PATH Trial becoming the first successful, large-scale randomized ...

WATERTOWN, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe ...

Proceeds to fund clinical development of DIAG723, a first-in-class, disease-modifying therapy designed to correct the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial ...

With a $125 million series B financing round, Diagonal Therapeutics has made a vertical move to advance its first-in-class ...

The positions in the table below reflect the Cure HHT's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links to the corresponding ...

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...

Patients with hereditary hemorrhagic telangiectasia (HHT), a rare genetic disorder that causes abnormal blood vessel formation, wage a lifelong battle against skin lesions, frequent nosebleeds and ...

Preliminary results indicate HHT patients are significantly impacted by bleeding events, with consistency in severity reporting at months one and three of the study Final study analysis will inform ...